Study summary

Under-the-skin efgartigimod did not beat placebo in chronic ITP

ADVANCE SC trial (efgartigimod) · 207 people, phase 3 · Published July 2026, American Journal of Hematology

13.7%sustained platelet response, vs 16.2% with placebo

What was tested

Subcutaneous efgartigimod, an FcRn blocker that lowers antibody levels, against placebo in adults with primary ITP.

What they found

What it means

Leaves the role of FcRn blockers in ITP unsettled.

Am J Hematol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.